Prostaglandin analogues in the treatment of glaucoma

被引:58
作者
Lindén, C
Alm, A
机构
[1] Umea Univ, Dept Ophthalmol, SE-90185 Umea, Sweden
[2] Uppsala Univ, Dept Ophthalmol, Uppsala, Sweden
关键词
D O I
10.2165/00002512-199914050-00006
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Prostaglandin (PG) analogues are a new class of ocular hypotensive drugs that have been developed for the treatment of open angle glaucoma. Two of these drugs, latanoprost and unoprostone, are presently commercially available. Latanoprost was introduced in 1996 in the US and Europe. Presently it enjoys the most widespread use and is the most well documented drug of this group. It reduces the intraocular pressure (IOP) by a mechanism of action different from other drugs; namely by increasing the uveoscleral outflow. The aqueous inflow is not affected. The optimal dose regimen is one drop of 50 mu g/ml once daily, which reduces the IOP by approximately 30% in patients with glaucoma. A more pronounced ocular hypotensive effect is demonstrated when latanoprost is combined with other glaucoma therapies, including beta-blockers, adrenergic and cholinergic agonists or carbonic anhydrase inhibitors. Latanoprost is well tolerated. The drug reaches a plasma concentration below that needed for stimulation of the FP-receptor, which may explain its favourable systemic tolerability profile. The major ocular adverse effect is increased iris pigmentation, which is due to increased synthesis of melanin in the melanocytes of the iris stroma. It is most frequently seen in green-brown eyes and it is probably permanent. A low frequency of cystoid macular oedema has also been reported, predominantly in predisposed eyes. Unoprostone was launched in Japan in 1994, but there is little experience with this drug outside the Japanese market and the documentation is more limited. Its main mechanism of action is on outflow, but this is not yet fully elucidated. The recommended dosage regimen is 1 drop of 1.2 mg/ml twice daily. No comparative studies in humans between the 2 drugs have yet been published.
引用
收藏
页码:387 / 398
页数:12
相关论文
共 108 条
[61]  
NAKAMATSU T, 1996, J EYE, V13, P439
[62]   PROSTAGLANDIN-F-2-ALPHA FUNCTIONS AS A LOCAL HORMONE ON HUMAN AIRWAYS [J].
NEWBALL, HH ;
KEISER, HR ;
LENFANT, C .
RESPIRATION PHYSIOLOGY, 1980, 41 (02) :183-197
[63]   A comparative study of the effects of timolol and latanoprost on blood flow velocity of the retrobulbar vessels [J].
Nicolela, MT ;
Buckley, AR ;
Walman, BE ;
Drance, SM .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1996, 122 (06) :784-789
[64]   INCREASED UVEOSCLERAL OUTFLOW AS A POSSIBLE MECHANISM OF OCULAR HYPOTENSION CAUSED BY PROSTAGLANDIN F-2-ALPHA-1-ISOPROPYLESTER IN THE CYNOMOLGUS MONKEY [J].
NILSSON, SFE ;
SAMUELSSON, M ;
BILL, A ;
STJERNSCHANTZ, J .
EXPERIMENTAL EYE RESEARCH, 1989, 48 (05) :707-716
[65]  
Ocklind A, 1996, INVEST OPHTH VIS SCI, V37, P716
[66]   Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections [J].
Ocklind, A .
EXPERIMENTAL EYE RESEARCH, 1998, 67 (02) :179-191
[67]   Latanoprost for uncontrolled glaucoma in a compassionate case protocol [J].
Patelska, B ;
Greenfield, DS ;
Liebmann, JM ;
Wand, D ;
Kushnick, H ;
Ritch, R .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1997, 124 (03) :279-286
[68]  
*PHARM UPJ, 1996, XAL PRESCR INF
[69]  
PROTA G, 1992, MELANINS MELANOGENES, P164
[70]  
PROTZMAN CE, 1990, INVEST OPHTH VIS SCI, V31, P2463